{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:07:46Z","timestamp":1792080466624,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03107-0","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:20:43Z","timestamp":1748532043000},"page":"709-720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical outcomes of off-label DOAC underdosing in Japanese patients with atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"given":"Akinori","family":"Sairaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"3107_CR1","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV et al (2024) ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 45:3314\u20133414","journal-title":"Eur Heart J"},{"key":"3107_CR2","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","volume":"76","author":"AJ Camm","year":"2020","unstructured":"Camm AJ, Cools F, Virdone S et al (2020) Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol 76:1425\u20131436","journal-title":"J Am Coll Cardiol"},{"key":"3107_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/bcp.14127","volume":"86","author":"J Santos","year":"2020","unstructured":"Santos J, Ant\u00f3nio N, Rocha M et al (2020) Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. Br J Clin Pharmacol 86:533\u2013547","journal-title":"Br J Clin Pharmacol"},{"key":"3107_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/clc.23586","volume":"44","author":"X Liu","year":"2021","unstructured":"Liu X, Huang M, Ye C et al (2021) Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta-analysis. Clin Cardiol 44:472\u2013480","journal-title":"Clin Cardiol"},{"key":"3107_CR5","doi-asserted-by":"publisher","first-page":"e007971","DOI":"10.1161\/CIRCOUTCOMES.121.007971","volume":"14","author":"X-L Zhang","year":"2021","unstructured":"Zhang X-L, Zhang X-W, Wang T-Y et al (2021) Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: A meta-analysis. Circ Cardiovasc Qual Outcomes 14:e007971","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3107_CR6","doi-asserted-by":"publisher","first-page":"e13819","DOI":"10.1111\/eci.13819","volume":"52","author":"C Sang","year":"2022","unstructured":"Sang C, Chen J, Sun J et al (2022) Off-label underdosing of four individual NOACs in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies. Eur J Clin Invest 52:e13819","journal-title":"Eur J Clin Invest"},{"key":"3107_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijcard.2022.04.062","volume":"362","author":"MQ Pereira","year":"2022","unstructured":"Pereira MQ, David C, Almeida AG et al (2022) Clinical effects of off-label reduced doses of direct oral anticoagulants: A systematic review and meta-analysis. Int J Cardiol 362:76\u201382","journal-title":"Int J Cardiol"},{"key":"3107_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40264-024-01476-8","volume":"48","author":"P Mongkhon","year":"2025","unstructured":"Mongkhon P, Singkham N, Ponok K et al (2025) Comparative effectiveness and safety of off-label underdosed direct oral anticoagulants in asian patients with atrial fibrillation: a systematic review and meta-analysis. Drug Saf 48:25\u201342","journal-title":"Drug Saf"},{"key":"3107_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","volume":"121","author":"HK Kim","year":"2021","unstructured":"Kim HK, Tantry US, Smith SC Jr et al (2021) The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 121:422\u2013432","journal-title":"Thromb Haemost"},{"key":"3107_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00228-023-03471-x","volume":"79","author":"A Sairaku","year":"2023","unstructured":"Sairaku A, Nakano Y (2023) Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants. Eur J Clin Pharmacol 79:579\u2013588","journal-title":"Eur J Clin Pharmacol"},{"key":"3107_CR11","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N et al (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF study. Circ J 76:2104\u20132111","journal-title":"Circ J"},{"key":"3107_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"3107_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692\u2013694","journal-title":"J Thromb Haemost"},{"key":"3107_CR14","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. (2024) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm. Accessed 12 Dec 2024."},{"key":"3107_CR15","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomized trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"3107_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1472-6963-4-38","volume":"4","author":"D Atkins","year":"2004","unstructured":"Atkins D, Eccles M, Flottorp S et al (2004) Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches. BMC Health Serv Res 4:38","journal-title":"BMC Health Serv Res"},{"key":"3107_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jjcc.2018.12.013","volume":"73","author":"H Inoue","year":"2019","unstructured":"Inoue H, Uchiyama S, Atarashi H et al (2019) Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance. J Cardiol 73:507\u2013514","journal-title":"J Cardiol"},{"key":"3107_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1253\/circj.CJ-18-0991","volume":"83","author":"N Murata","year":"2019","unstructured":"Murata N, Okumura Y, Yokoyama K et al (2019) Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF registry. Circ J 83:727\u2013735","journal-title":"Circ J"},{"key":"3107_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11239-019-01934-6","volume":"48","author":"T Ikeda","year":"2019","unstructured":"Ikeda T, Ogawa S, Kitazono T et al (2019) Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings. J Thromb Thrombolysis 48:653\u2013660","journal-title":"J Thromb Thrombolysis"},{"key":"3107_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jjcc.2019.07.007","volume":"75","author":"H Inoue","year":"2020","unstructured":"Inoue H, Umeyama M, Yamada T et al (2020) Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study. J Cardiol 75:208\u2013215","journal-title":"J Cardiol"},{"key":"3107_CR21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1536\/ihj.20-335","volume":"61","author":"Y Wakamatsu","year":"2020","unstructured":"Wakamatsu Y, Nagashima K, Watanabe R et al (2020) Clinical outcomes of off-label underdosing of direct oral anticoagulants after ablation for atrial fibrillation. Int Heart J 61:1165\u20131173","journal-title":"Int Heart J"},{"key":"3107_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00380-019-01457-3","volume":"35","author":"N Yagi","year":"2020","unstructured":"Yagi N, Suzuki S, Arita T et al (2020) Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Heart Vessels 35:110\u2013117","journal-title":"Heart Vessels"},{"key":"3107_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.amjcard.2020.09.053","volume":"139","author":"J Ohno","year":"2021","unstructured":"Ohno J, Sotomi Y, Hirata A et al (2021) Dose of direct oral anticoagulants and adverse outcomes in Asia. Am J Cardiol 139:50\u201356","journal-title":"Am J Cardiol"},{"key":"3107_CR24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1007\/s00380-021-01810-5","volume":"36","author":"H Atarashi","year":"2021","unstructured":"Atarashi H, Uchiyama S, Inoue H et al (2021) Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study. Heart Vessels 36:1410\u20131420","journal-title":"Heart Vessels"},{"key":"3107_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/joa3.12520","volume":"37","author":"T Yamashita","year":"2021","unstructured":"Yamashita T, Koretsune Y, Nagao T et al (2021) Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two-year postmarketing surveillance study (ETNA-AF-Japan). J Arrhythm 37:370\u2013383","journal-title":"J Arrhythm"},{"key":"3107_CR26","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1253\/circj.CJ-20-1244","volume":"85","author":"K Kusano","year":"2021","unstructured":"Kusano K, Sugishita N, Akao M et al (2021) Effectiveness and safety of rivaroxaban by general practitioners: A multicenter, prospective study in Japanese patients with non-valvular atrial fibrillation (GENERAL). Circ J 85:1275\u20131282","journal-title":"Circ J"},{"key":"3107_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jjcc.2022.03.006","volume":"80","author":"S Miyazaki","year":"2022","unstructured":"Miyazaki S, Miyauchi K, Hayashi H et al (2022) Trends of anticoagulant use and outcomes of patients with non-valvular atrial fibrillation: Findings from the RAFFINE registry. J Cardiol 80:41\u201348","journal-title":"J Cardiol"},{"key":"3107_CR28","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1055\/s-0042-1744543","volume":"122","author":"H Arashi","year":"2022","unstructured":"Arashi H, Yamaguchi J, Hagiwara N et al (2022) Rivaroxaban underdose for atrial fibrillation with stable coronary disease: The AFIRE trial findings. Thromb Haemost 122:1584\u20131593","journal-title":"Thromb Haemost"},{"key":"3107_CR29","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1253\/circj.CJ-23-0143","volume":"87","author":"M Akao","year":"2023","unstructured":"Akao M, Inoue H, Yamashita T et al (2023) Relationship between direct oral anticoagulant doses and clinical outcomes in elderly patients with non-valvular atrial fibrillation: ANAFIE registry sub-analysis. Circ J 87:1765\u20131774","journal-title":"Circ J"},{"key":"3107_CR30","doi-asserted-by":"publisher","first-page":"645479","DOI":"10.3389\/fphar.2021.645479","volume":"12","author":"N-N Shen","year":"2021","unstructured":"Shen N-N, Zhang C, Wang N et al (2021) Effectiveness and safety of under or over-dosing of direct oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of 148,909 patients from 10 real-world studies. Front Pharmacol 12:645479","journal-title":"Front Pharmacol"},{"key":"3107_CR31","doi-asserted-by":"publisher","first-page":"107602962311794","DOI":"10.1177\/10760296231179439","volume":"29","author":"N-N Shen","year":"2023","unstructured":"Shen N-N, Ferroni E, BarbielliniAmidei C et al (2023) An updated pooled analysis of off-label under and over-dosed direct oral anticoagulants in patients with atrial fibrillation. Clin Appl Thromb Hemost 29:10760296231179440","journal-title":"Clin Appl Thromb Hemost"},{"key":"3107_CR32","doi-asserted-by":"publisher","first-page":"euad288","DOI":"10.1093\/europace\/euad288","volume":"25","author":"Y-H Chan","year":"2023","unstructured":"Chan Y-H, Chan C-Y, Chen S-W et al (2023) Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies. Europace 25:euad288","journal-title":"Europace"},{"key":"3107_CR33","unstructured":"Ministry of Health, Labour and Welfare, Japan. (2024) National Health and Nutrition Survey 2017. Available at: https:\/\/www.e-stat.go.jp. Accessed 12 Dec 2024."},{"key":"3107_CR34","unstructured":"National Center for Health Statistics. (2024) National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available at: https:\/\/www.cdc.gov\/nchs\/nhanes\/index.htm. Accessed 12 Dec 2024."},{"key":"3107_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000520857","volume":"51","author":"M Naganuma","year":"2022","unstructured":"Naganuma M, Inatomi Y, Yonehara T et al (2022) Underdosed direct oral anticoagulants in atrial fibrillation patients reduce stroke severity and improve outcome. Cerebrovasc Dis 51:473\u2013480","journal-title":"Cerebrovasc Dis"},{"key":"3107_CR36","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","volume":"383","author":"K Okumura","year":"2020","unstructured":"Okumura K, Akao M, Yoshida T et al (2020) Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 383:1735\u20131745","journal-title":"N Engl J Med"},{"key":"3107_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","volume":"18","author":"C Wilkinson","year":"2020","unstructured":"Wilkinson C, Wu J, Searle SD et al (2020) Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med 18:401","journal-title":"BMC Med"},{"key":"3107_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejim.2011.09.003","volume":"23","author":"E Pijpers","year":"2012","unstructured":"Pijpers E, Ferreira I, Stehouwer CDA, NieuwenhuijzenKruseman AC (2012) The frailty dilemma: review of the predictive accuracy of major frailty scores. Eur J Intern Med 23:118\u2013123","journal-title":"Eur J Intern Med"},{"key":"3107_CR39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jamda.2024.01.015","volume":"25","author":"SJ Liau","year":"2024","unstructured":"Liau SJ, Zhao M, Hamada S et al (2024) Deprescribing opportunities for frail residents of nursing homes: a multicenter study in Australia, China, Japan, and Spain. J Am Med Dir Assoc 25:876\u2013883","journal-title":"J Am Med Dir Assoc"},{"key":"3107_CR40","doi-asserted-by":"publisher","first-page":"102039","DOI":"10.1016\/j.eclinm.2023.102039","volume":"63","author":"GF Romiti","year":"2023","unstructured":"Romiti GF, Corica B, Proietti M et al (2023) Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry. EClinicalMedicine 63:102039","journal-title":"EClinicalMedicine"},{"key":"3107_CR41","doi-asserted-by":"publisher","first-page":"e003109","DOI":"10.1136\/openhrt-2024-003109","volume":"12","author":"CY Cheng","year":"2025","unstructured":"Cheng CY, Lian TY, Zhu XJ et al (2025) Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF. Open Heart 12:e003109","journal-title":"Open Heart"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03107-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03107-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03107-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:28:15Z","timestamp":1757176095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03107-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["3107"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03107-0","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"30 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}